If you have been reading about aliquoting and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
Aseptic technique reduces microbial and particulate contamination when a peptide solution will be used in cell culture or other sensitive applications. Work in a clean area, use sterile containers and filtered tips, and avoid touching vial interiors. Preparing aliquots immediately after dissolution limits repeated temperature cycling, which is a common cause of aggregation and activity loss. Low-binding plastic tubes are preferred for peptides that adsorb to surfaces, especially hydrophobic or positively charged sequences. Labels should record identity, solvent, concentration, and preparation date so that later use can be traced.
Shipping and short-term transfer require attention to temperature control and physical stability. Frozen solutions are commonly sent on dry ice, while lyophilized powders may travel with gel packs or insulated packaging. Thawing should be done slowly on ice or in a refrigerator, not by vigorous heating, and the solution should be mixed gently before use. Temperature loggers can document excursions during transit, but their presence does not prove that a peptide remained stable. Analytical checks such as chromatography or mass spectrometry can verify identity and purity after storage or shipping.
Practical handling begins with an inventory record that links each vial to a lot number, synthesis date, and purity certificate. Before opening a container, allow it to equilibrate to room temperature to prevent condensation on the powder. Weighing or transferring should occur in a low-humidity environment using tools that minimize static and adsorption. Hygroscopic peptides may gain water quickly, changing mass and concentration estimates. Recording the container's initial mass and any visible changes supports later reconciliation of material.
Reconstitution introduces additional variables: solvent choice, pH, ionic strength, and filtration. Many sequences dissolve readily in water, while hydrophobic ones may need acetonitrile, dimethyl sulfoxide, or a small amount of base. Adding solvent slowly and avoiding vigorous vortexing can reduce foaming and shear-induced aggregation. If the solution appears cloudy, filtration may remove particulates but can also remove aggregated peptide and alter concentration. A clear solution does not by itself confirm correct sequence or purity, so analytical checks remain necessary.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder or frozen solution | Powder typically more stable for long-term storage; solutions require colder conditions. |
| Recommended reconstitution solvent | Water, buffer, or water-miscible organic solvent | Matches peptide hydrophobicity; test small portion if unknown. |
| Typical working aliquot size | Single-use volumes in low-binding tubes | Reduces repeated warming and cooling and contamination risk. |
| Short-term shipping condition | Dry ice for frozen solutions; gel packs for powders | Insulation and temperature logging help document transit. |
| Common purity check | Reverse-phase HPLC with UV detection | Often paired with mass spectrometry for identity confirmation. |
When a peptide arrives, the vial should be inspected for damage, and its label, lot number, and accompanying analytical data should be recorded. Cold vials should equilibrate to room temperature before opening to prevent condensation on the powder. Moisture uptake can reduce stability and complicate accurate weighing or reconstitution. Inventory systems that track date, quantity, and storage location help prevent unnecessary temperature cycling. Personnel should follow institutional or manufacturer instructions for any specific peptide.
Reconstitution is often performed with sterile water, buffer, or a water-miscible organic solvent, depending on solubility. The solvent should be added gently along the vial wall, and the solution mixed by gentle swirling rather than vigorous vortexing, which can cause foaming and surface denaturation. Some sequences require a small amount of base or acid to dissolve, followed by pH adjustment. Preparing a concentrated stock solution can simplify later dilution, but the stock itself may have limited stability. Records of solvent, concentration, and date support reproducibility.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, and conformation. The amide backbone can hydrolyze under acidic or basic conditions, while side chains such as methionine, cysteine, and tryptophan are prone to oxidation. Aggregation may occur when hydrophobic regions associate, especially near surfaces or at high concentration. Because these pathways differ among peptides, no single storage condition applies to all sequences. Stability studies therefore examine each peptide under defined temperature, pH, and humidity ranges.
Temperature is a primary variable because most degradation reactions slow as thermal energy decreases. Lyophilized powders are commonly held at -20 °C for routine work and at -80 °C for longer archival periods, though exact recommendations depend on the peptide. Solutions are less stable than dry powders in many cases, and repeated freeze-thaw cycles can promote aggregation or precipitation. Inert atmospheres, such as argon or nitrogen, can limit oxidation for oxygen-sensitive sequences. Desiccants reduce water activity, which lowers hydrolysis rates during storage.
Light exposure can damage aromatic residues and certain labels, so amber vials or opaque containers are often used. pH control matters in solution, as extreme acidity or alkalinity accelerates backbone cleavage; buffers may also introduce ions that affect solubility. Microbial growth is a concern for aqueous preparations that lack preservatives, though many research peptides are handled in sterile or low-bioburden conditions. Container materials can adsorb peptides, particularly hydrophobic or positively charged sequences, reducing recovery. These factors interact, meaning storage decisions balance chemical stability, physical state, and intended use.
== Medical uses == The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include SGLT2 inhibitors as a first line pharmacological therapy for type 2 diabetes (usually together with metformin), specifically in patients with chronic kidney disease, cardiovascular disease or heart failure. A systematic review and network meta-analysis comparing SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors demonstrated that use of SGLT2 inhibitors was associated with a 1% reduction in death compared with placebo or no treatment. Another systematic review discussed the mechanisms by which SGLT-2 inhibitors improve cardio-renal function in patients with type 2 diabetes, emphasizing the impacts in improving neural tone. A meta-analysis including 13 cardiovascular outcome trials found that SGLT-2 inhibitors reduce the risk for three-point major adverse cardiovascular events (MACE), especially in subjects with an estimated glomerular filtration rate (eGFR) below 60 ml/min, whereas GLP-1 receptor agonists were more beneficial in persons with higher eGFR. Likewise, the risk reduction due to SGLT-2 inhibitors was larger in populations with a higher proportion of albuminuria, but this relationship was not observed for GLP-1 receptor agonists. This suggests a differential use of the two substance classes in patients with preserved and reduced renal function or with and without diabetic nephropathy, respectively. Two reviews have concluded that SGLT2 inhibitors benefit patients with atherosclerotic major adverse cardiovascular events.
Nevertheless, the European judges acknowledged the Advocate General's concerns, stating that there must be clear procedures to allow substances to be added to the permitted list based on scientific evidence. They also said that any refusal to add the product to the list must be open to challenge in the courts.
To the east and north of the rebuilt central city are a stretch of old neighbourhoods (Danton, Saint-Vincent, Graville, Massillon, etc.) which were spared the bombings of World War II. The buildings, usually in brick, dated to the 19th and the first half of the 20th centuries. The shops are concentrated along several major roads in the Rond-Point neighbourhood. During the 1990s and 2000s, these neighborhoods have seen major redevelopments, particularly in the context of an OPAH: improvement of habitat by rehabilitation or reconstruction, creation of public facilities, and revitalization of business. At the end of the 20th century and beginning of the 21st century, the area around the railway station has undergone a major transformation. As the station is the gateway to the city with the main avenues intersecting here. New buildings have sprung up (University of Le Havre, the conservatory, headquarters of the SPB (Provident Society Bank), and of CMA CGM, Novotel, Matmut, new CCI) some of which were designed by renowned architects. The bus station, certified NF since 2005, has been refurbished. North of the station, another construction project in place of the dilapidated island of Turgot-Magellan will be opened in 2013, including 12,500 m2 (135,000 sq ft) of office space and an eight-storey hotel, complete with shops on the ground-floor.
Sources: en.wikipedia.org
==== Killing of Israeli civilians ==== The elimination of the State of Israel has been a primary goal for Hezbollah. Hezbollah has been accused of "only [regarding] the Jews living in Israel as Zionists, who should be killed". Throughout the war Hezbollah announced the targeting of civilian homes. On 12 November 2023, Hezbollah fired an anti-tank missile killing an employee of the Israel Electric Corporation who was conducting repair work and injured 13 other Israelis, including six other employees of the Israeli Electric Corporation. The most notable of Hezbollah's attacks on civilians was on 27 July 2024 in the Majdal Shams attack, when Hezbollah fired an Iranian-made Falaq-1 rocket at Majdal Shams, a Druze town in the Golan Heights. The rocket hit a football pitch killing 12 Druze children and injuring at least 42 others. Another attack by Hezbollah resulted in civilian casualties on 9 July 2024, when a rocket struck a couple's car just south of their hometown of Ortal. Additionally, a couple walking their dog in Kiryat Shmona was killed by shrapnel from a Hezbollah rocket on 9 October 2024. On 26 December 2023, a Hezbollah anti-tank missile impacted near a Channel 13 News team while they were interviewing a farmer at Dovev for an article following a prior Hezbollah assault that killed a 56-year-old employee of the Israel Electric Corporation, and injured five workers who were repairing electric lines. Throughout the conflict, Hezbollah fired thousands of inaccurate munitions at Israel and the Golan Heights, killing and injuring civilians and destroying houses.
This 1686-amino acid protein belongs to the ADAMTS family and is one of 19 members known in humans. It is a large, multi-domain enzyme that undergoes extensive post-translational modifications, including N- and O-linked glycosylation, chondroitin sulfate attachment, and potential C-mannosylation and O-fucosylation of the thrombospondin (TSP) type 1 domains. The domain structure from the N-terminus to the C-terminus consists of:
=== Nutrition === Calcium is a common constituent of multivitamin dietary supplements, but the composition of calcium complexes in supplements may affect its bioavailability which varies by solubility of the salt involved: calcium citrate, malate, and lactate are highly bioavailable, while the oxalate is less. Other calcium preparations include calcium carbonate, calcium citrate malate, and calcium gluconate. The intestine absorbs about one-third of uncomplexed calcium consumed, and plasma calcium level is then regulated by the kidneys.
Sources: en.wikipedia.org
== Industry references == These terms generally apply broadly across industries and institutions. In addition, they may have very specific meanings and requirements for specific products, regulations, and industries. Some examples:
== Clinical studies == PF-04455242 reached phase 1 clinical trials for bipolar depression prior to the discontinuation of its development in 2010. Its development was discontinued upon unfavorable toxicological findings in animals that had been exposed to the drug for 3 months. Along with JDTic, which was also discontinued due to toxicity findings early in clinical trials, PF-04455242 was one of the first KOR antagonists to be developed for potential treatment of psychiatric disorders. It was in phase 1 trials by 2009 and was first described in the scientific literature by 2010.
Ewan McGregor at IMDb Ewan McGregor at the Internet Broadway Database Ewan McGregor at the TCM Movie Database (archived) Ewan McGregor at the British Film Institute Ewan McGregor at the BFI's Screenonline Ewan McGregor at Rotten Tomatoes Ewan McGregor at Emmys.com
Following extended discussions with Richwood Pharmaceuticals regarding the resolution of a large number of issues related to the company's numerous violations of FDA regulations, the FDA formally approved the first Obetrol labeling/sNDA revisions in 1996, including a name change to Adderall and a restoration of its status as an approved drug product. In 1997 Richwood Pharmaceuticals was acquired by Shire Pharmaceuticals in a $186 million transaction. Richwood Pharmaceuticals, which later merged with Shire, introduced the Adderall brand in 1996 as an instant-release tablet. In 2006, Shire agreed to sell rights to the Adderall name for the instant-release form of the medication to Duramed Pharmaceuticals. DuraMed Pharmaceuticals was acquired by Teva Pharmaceuticals in 2008 during their acquisition of Barr Pharmaceuticals, including Barr's Duramed division. The first generic version of Adderall IR was introduced to the market in 2002. Later on, Barr and Shire reached a settlement agreement permitting Barr to offer a generic form of the extended-release drug beginning in April 2009.
Sources: en.wikipedia.org
Multiple freezing and thawing events can cause aggregation, precipitation, or loss of soluble peptide. Dividing a solution into single-use aliquots before freezing reduces this risk. If multiple cycles are unavoidable, stability should be checked after thawing.
Low-binding polypropylene tubes are often used because some peptides adsorb to glass or standard plastic. The choice depends on peptide hydrophobicity and charge. Containers should be clean, sterile when needed, and compatible with the solvent.
Reverse-phase chromatography can assess purity and retention time, while mass spectrometry confirms molecular mass. These methods can detect degradation products and sequence-related impurities. Results are compared with a reference sample or initial analysis.
Work quickly in a dry environment and keep the container closed when not in use. Equilibrate sealed vials to room temperature before opening to reduce condensation. Record mass changes, as absorbed water can affect concentration calculations.